ConductScience.org, home

Paper17538162

Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.

Siu LL and 13 others. J Clin Oncol, 2007. Cited by 106 papers, by iCite.

Cite this record

ConductScience Library. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. Papers, record 17538162. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538162

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
PubMed
Journal
J Clin Oncol
PubMed
Year
2007
PubMed
Publication types
Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
106
iCite
Relative citation ratio, by iCite
2.36
iCite
Revised in PubMed
2018-12-01
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Siu LLLillian L
2Soulieres DDenis
3Chen EXEric X
4Pond GRGregory R
5Chin SFSoo F
6Francis PPeggy
7Harvey LLuc
8Klein MMeri
9Zhang WWenjiang
10Dancey JJanet
11Eisenhauer EAElizabeth A
12Winquist EEric
13Princess Margaret Hospital Phase II ConsortiumGroup
14National Cancer Institute of Canada Clinical Trials Group StudyGroup

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Carcinoma, Squamous CellMajor topic
CisplatinMajor topic
ErbB ReceptorsMajor topic
Head and Neck NeoplasmsMajor topic
QuinazolinesMajor topic
Adult
Aged
Aged, 80 and over
Erlotinib Hydrochloride
Female
Humans
Male
Middle Aged

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
N01-CM-17107NCI NIH HHSUnited StatesPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00030576Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerResults

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17538157Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.https://conductscience.org/library/papers/17538157

Source PubMed

Download CSV of comments and corrections

Cited by52

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 106 citations.

PMIDTitleJournalYearIn PapersSource
40881676Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations.Front Immunol2025https://conductscience.org/library/papers/40881676PubMed
40296503Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early-Stage Squamous Cell Carcinoma of the Head and Neck: Long-Term Follow-Up.Head Neck2025https://conductscience.org/library/papers/40296503PubMed
39339232Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.Pharmaceutics2024https://conductscience.org/library/papers/39339232PubMed
37844343Multi-kinase compensation rescues EGFR knockout in a cell line model of head and neck squamous cell carcinoma.Arch Oral Biol2023https://conductscience.org/library/papers/37844343PubMed
36646686Targeted therapy for head and neck cancer: signaling pathways and clinical studies.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36646686PubMed
35453483Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer.Biomedicines2022https://conductscience.org/library/papers/35453483PubMed
34771633Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma.Cancers (Basel)2021https://conductscience.org/library/papers/34771633PubMed
33335306Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC.Oncogene2021https://conductscience.org/library/papers/33335306PubMed
31933185Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.Pharmaceut Med2019https://conductscience.org/library/papers/31933185PubMed
29568372Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma.Oncotarget2018https://conductscience.org/library/papers/29568372PubMed
29371473Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas.Oncologist2018https://conductscience.org/library/papers/29371473PubMed
29232766Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.Cell Prolif2018https://conductscience.org/library/papers/29232766PubMed
29113454Modulators of Redox Metabolism in Head and Neck Cancer.Antioxid Redox Signal2018https://conductscience.org/library/papers/29113454PubMed
28382569Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.Drugs2017https://conductscience.org/library/papers/28382569PubMed
27924064Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma.Oncotarget2017https://conductscience.org/library/papers/27924064PubMed
27110122Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.Onco Targets Ther2016https://conductscience.org/library/papers/27110122PubMed
26927178Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC).Cancers (Basel)2016https://conductscience.org/library/papers/26927178PubMed
26918562Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.Head Neck2016https://conductscience.org/library/papers/26918562PubMed
24566736Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Clin Pharmacokinet2014https://conductscience.org/library/papers/24566736PubMed
24429877A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.Clin Cancer Res2014https://conductscience.org/library/papers/24429877PubMed

See all 52 cited byDownload CSV of cited by

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CISPLATINCHEMBL11359Results1https://conductscience.org/library/drugs/CHEMBL11359ChEMBL
ERLOTINIBCHEMBL553Results1https://conductscience.org/library/drugs/CHEMBL553ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17538162

GET https://conductscience.org/api/papers/v1/17538162/cited_by?page=2